Test Price
2,800 AED✅ Home Collection Available
G6PC3 Gene Neutropenia (Severe Congenital Type 4, Autosomal Recessive) Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity and Specificity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Complimentary VIP mobile phlebotomy and ISO‑certified cold‑chain home collection (8 AM – 11 PM). Accepts whole blood (EDTA), extracted DNA, or FTA card.
- Clinical Guidance: Complimentary telephonic post‑test consultation with a DHA‑licensed specialist to interpret results and plan next steps.
- Insurance & Billing: Direct billing verification and coverage check via WhatsApp: +971 54 548 8731.
- Pre‑Test Requirement: A pre‑test genetic counselling session and construction of a family pedigree chart are strongly advised.
Test Overview & Methodology
This next‑generation sequencing (NGS) test comprehensively analyses the entire coding region of the G6PC3 gene to identify pathogenic variants responsible for severe congenital neutropenia type 4 (autosomal recessive). The assay is ordered primarily by pediatricians, dermatologists, and clinical geneticists to confirm diagnosis, guide hematopoietic stem cell transplant eligibility, and inform family‑planning decisions.
| Feature | Our G6PC3 NGS Test | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Methodology | Full‑gene Next‑Generation Sequencing (NGS) with copy number variant analysis | Sanger sequencing of individual exons |
| Analytical Precision | >99.9% sensitivity/specificity; detects SNVs, indels, and large rearrangements | ~95% sensitivity; misses deep intronic/copy number changes |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Sample Requirements | 3 mL whole blood (EDTA), or extracted DNA, or one drop on FTA Card | 5–10 mL blood; DNA extraction delays |
| Interpretation Support | DHA‑licensed geneticist review & post‑test tele‑guidance | Automated report only |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“We deeply understand the concern that a suspected severe congenital neutropenia diagnosis brings to a family. Molecular confirmation of the G6PC3 variant is a pivotal step, yet it must always be integrated with the full clinical picture — neutrophil counts, bone marrow morphology, and infectious history — to craft a safe, individualised care plan.”
Advisory: Medication Continuation
⚠️ Medication Warning
Do not discontinue any prescribed medication, including granulocyte colony‑stimulating factor (G-CSF) or prophylactic antibiotics, without prior consultation with your managing physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Individuals with an active, uncontrolled life‑threatening infection or hemodynamic instability; persons unable to provide informed consent (minors require legal guardian consent).
- Emergency Red Flags: If the patient develops sudden fever >38.3°C with an absolute neutrophil count (ANC) <200/µL, seek immediate emergency medical attention. Do not wait for genetic test results.
Patient FAQ & Clinical Guidance
1. What is the G6PC3 gene neutropenia test, and why is it ordered?
Snippet: This advanced NGS test analyzes the entire G6PC3 gene for pathogenic variants causing severe congenital neutropenia type 4, an autosomal recessive disorder that impairs neutrophil production.
2. Why is pre‑test genetic counselling essential before giving a sample?
Snippet: Pre‑genetic counselling helps families understand autosomal recessive inheritance, empowers informed decision‑making, and prepares them emotionally for possible pathogenic or variant‑of‑uncertain‑significance results.
3. How accurate is the NGS technology for detecting G6PC3 mutations?
Snippet: Our NGS platform delivers over 99.9% analytical sensitivity and specificity for all coding exons and flanking intronic regions of the G6PC3 gene, validated according to CAP and CLIA international standards.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent for testing and data processing adheres to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Results are interpreted and reported by DHA-licensed clinical geneticists. Our laboratory holds ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | G6PC3 Gene Neutropenia (Severe Congenital Type 4, Autosomal Recessive) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) with copy number variant analysis |
| ICD-10-CM Code | D70.0 (Congenital agranulocytosis) |
| LOINC Code | 21633-4 (Gene sequencing, targeted) |
| DHA Facility License & Laboratory Address | DHA Facility License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians